Press Releases

March 25, 2021
– Dosed first patients in Phase 1 study with new product candidate A3907 – – First patient dosed in ASSERT global Phase 3 study of odevixibat for Alagille syndrome – – EMA & FDA reviewing odevixibat for PFIC, currently no plans for FDA advisory committee meeting – – Achievement of important
February 26, 2021
– Calls to unite global communities affected by rare diseases – – Albireo supports increasing education and advances in research for rare cholestatic liver diseases – BOSTON , Feb. 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company
February 18, 2021
Conference call and webcast to be held at 10:00 a.m. ET BOSTON , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live
February 17, 2021
BOSTON , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock.
February 11, 2021
– Company outlining large global rare cholestatic liver disease opportunity – – Advancing plans for anticipated odevixibat U.S. and EU launch, with focus on market access – – Expansion opportunity beyond PFIC and beyond odevixibat – – Commercial management to host conference call and webcast today
January 22, 2021
Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases BOSTON , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid